查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046659

流行性胸膜炎疼痛市場－全球產業規模、佔有率、趨勢、機會、預測：按診斷、治療、給藥途徑、最終用戶、地區和競爭對手分類，2021-2031年

Pleurodynia Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Diagnosis, By Treatment, By Mode of Administration, By End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球流行性胸膜炎疼痛市場預計將從 2025 年的 1.5211 億美元成長到 2031 年的 2.0748 億美元，複合年成長率為 5.31%。

該市場專注於博恩霍爾姆病（一種主要由B組克沙奇病毒引起的病毒性疾病，表現為急性、痙攣性胸腹痛）的治療和症狀管理策略。推動該市場成長的關鍵因素包括腸病毒感染疾病率的上升以及分子診斷技術的進步，這些進步加速了病毒性肌痛與更嚴重的心肺疾病的鑑別診斷。例如，根據台灣疾病管制署的報告，到2025年1月，因腸病毒感染疾病而就診的門診和急診患者每週將超過12,350人次，這凸顯了持續的臨床負擔，並將推動對鎮痛和抗炎治療的需求。然而，由於胸膜炎性疼痛的症狀特異性，常常與心肌梗塞和肺動脈栓塞等危及生命的緊急情況相似，因此經常被誤診，這對市場擴張構成了挑戰。這種診斷上的不確定性常常導致醫療專業人員優先進行全面的心臟檢查，而非即時處理病毒症狀，從而延誤了適當的支持治療，並限制了針對胸膜炎疼痛的治療藥物的商業性可行性。此外，低成本的非非專利非類固醇消炎劑（NSAIDs）作為標準療法的廣泛應用，造成了低利潤環境，阻礙了製藥業對專門針對該適應症的新型專利製劑進行大量投資。

市場概覽
預測期 2027-2031
市場規模：2025年 1.5211億美元
市場規模：2031年 2.0748億美元
複合年成長率：2026-2031年 5.31%
成長最快的細分市場 口服
最大的市場 北美洲

市場促進因素

柯薩奇病毒B和其他腸病毒感染疾病的日益流行是全球流行性胸膜炎疼痛市場的主要促進因素。隨著病例數的增加，強力的症狀治療和準確的鑑別診斷變得至關重要，這迫使醫療系統加強鎮痛方案，並引入快速檢測方法，以區分博恩霍爾姆病與其他急性胸痛病因。根據台灣疾病管制署統計，2025年9月台灣每週因腸病毒感染疾病就診的門診和急診人數達到8313人次，顯示即使在傳統高峰期之外，對支持性治療的需求依然持續存在。病毒株的多樣性加劇了這一情況，其中包括腸病毒D68。根據美國疾病管制與預防中心（CDC）統計，2025年6月，腸病毒D68佔報告腸病毒檢體的61.6%，進一步凸顯了開發更先進治療方法的必要性。同時，廣譜抗病毒藥物和疫苗研發投入的增加正在改變市場格局，加速開發針對小核糖核酸病毒科（包括B組克沙奇病毒）的新型藥物。公共和私人資金正不斷投入，將基礎病毒學研究與臨床應用結合，旨在推出標靶治療，提供超越特異性鎮痛的療效。例如，根據BioWorld報道，美國高級研究計畫署（ARPA-H）於2025年10月向西奈山醫療中心撥款約1,180萬美元，用於開發廣譜抗病毒療法。如此巨額的資金對於推進候選藥物的臨床試驗、推出首個針對胸膜炎疼痛的緩解疾病治療方法以及顯著提升該領域的商業性潛力至關重要。

市場挑戰

全球流行性胸膜炎疼痛市場成長的主要障礙之一是博恩霍爾姆病的頻繁誤診，這主要是因為其臨床症狀與危及生命的心臟疾病相似。胸膜炎疼痛的特徵性痙攣性胸痛通常與心肌梗塞或肺動脈栓塞的症狀非常相似，導致醫療專業人員優先進行全面的心臟疾病排除檢查，而不是即時處理病毒症狀。這種診斷上的模糊性延誤了鎮痛和抗發炎治療的合理應用，導致胸膜炎疼痛特異性治療方法的商業性機會減少，標靶治療方法的整體市場規模縮小。這個診斷難題尤其棘手，因為儘管致病病毒的潛在盛行率很高，但在對特定流行性胸膜炎疼痛的需求背景下，它往往被忽略。例如，根據英國衛生安全局的報告，2025年11月檢體的呼吸道檢體中腸病毒和鼻病毒的陽性率約為20.3%。儘管病毒流行率如此之高，但市場並未充分利用這群患者。原因在於，這些病例中的大多數並未被確診為腸病毒性肌痛，而是被臨床歸類為非特異性胸痛或排除心臟疾病的診斷，這限制了市場潛在的收入。

市場趨勢

由於迫切需要緩解劇烈痙攣性胸痛，同時避免鴉片類藥物依賴的風險，胸膜炎性疼痛的臨床治療正迅速轉向非鴉片類鎮痛。這一市場轉變的特徵是新型鈉通道抑制劑的出現和商業化，這些抑制劑特異性針對與病毒性肌痛相關的周邊疼痛訊號，為目前作為標準治療的常用非類固醇消炎劑(NSAIDs) 提供了一種更先進的替代方案。該領域的一項重要進展是，根據 Vertex Pharmaceuticals 報道，美國食品藥物管理局(FDA) 於 2025 年 1 月核准了First-in-Class的口服 NaV1.8 疼痛訊號抑制劑 suzetrigine 上市。該藥物直接滿足了美國每年約 8000 萬患者的急性疼痛管理需求，並在日益重視減少急性病毒性疾病鴉片類藥物使用的治療方案的背景下，為醫療專業人員提供了一種強效的標靶治療選擇。同時，mRNA技術在腸病毒感染疾病的應用正在革新針對小核糖核酸病毒科（包括B組克沙奇病毒）的預防和治療性介入的研發。這一趨勢利用了mRNA平台固有的適應性，能夠快速重新設計疫苗以匹配流行病毒株，從而顯著縮短傳統去活化疫苗候選藥物漫長的研發週期。例如，2025年2月發表於《免疫學前沿》（Frontiers in Immunology）的一項研究表明，一種靶向腸病毒A71 VP1蛋白的核苷修飾mRNA候選疫苗在臨床前模型中對致命性病毒感染表現出100%的保護作用。這些令人鼓舞的結果凸顯了mRNA技術在針對引起博恩霍爾姆病的特定病毒提供精準保護方面的潛力，標誌著治療方式從單純的對症治療轉向能夠改變疾病進程的治療方法。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球流行性胸膜炎疼痛市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型診斷（血液檢查、培養檢查、X光檢查）
    • 治療方法（止痛藥、免疫球蛋白）
    • 依給藥途徑（口服、注射或靜脈輸注）
    • 依最終用戶（醫院、藥局等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美流行性胸膜炎疼痛市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲流行性胸膜炎疼痛的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區流行性胸膜炎疼痛市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲流行性胸膜炎疼痛的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲流行性胸膜炎疼痛的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球流行性胸膜炎疼痛市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc
  • Sanofi SA
  • Johnson & Johnson
  • Merck & Co Inc.
  • GlaxoSmithKline PLC
  • Reckitt Benckiser PLC
  • Bayer AG
  • Novartis AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17530

The Global Pleurodynia Treatment Market is projected to expand from USD 152.11 Million in 2025 to USD 207.48 Million by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 5.31%. This market encompasses therapeutic and symptomatic management strategies for Bornholm disease, a viral illness primarily caused by Group B Coxsackieviruses that manifests as acute spasmodic chest and abdominal pain. Key drivers of this growth include the rising incidence of enteroviral infections and advancements in molecular diagnostics, which enable quicker differentiation of viral myalgia from more critical cardiac or pulmonary conditions. For instance, the Taiwan Centers for Disease Control reported over 12,350 weekly outpatient and emergency visits for enterovirus infections in January 2025, underscoring the ongoing clinical burden that fuels demand for analgesic and anti-inflammatory treatments. Market expansion is, however, challenged by frequent misdiagnosis of pleurodynia, as its non-specific symptoms often mimic life-threatening emergencies like myocardial infarction or pulmonary embolism. This diagnostic uncertainty often leads healthcare providers to prioritize extensive cardiac workups over immediate viral symptom management, thereby delaying appropriate supportive care and constricting the commercial viability of targeted pleurodynia treatments. Additionally, the prevalence of low-cost generic non-steroidal anti-inflammatory drugs as the standard of care creates a low-margin environment, which discourages significant pharmaceutical investment in developing novel proprietary formulations specifically for this indication.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 152.11 Million
Market Size 2031USD 207.48 Million
CAGR 2026-20315.31%
Fastest Growing SegmentOral
Largest MarketNorth America

Market Driver

The increasing prevalence of Coxsackie B virus and other enteroviral infections serves as a primary driver for the Global Pleurodynia Treatment Market. The rising number of cases necessitates robust symptomatic management and precise diagnostic differentiation, compelling healthcare systems to enhance analgesic protocols and implement rapid testing to distinguish Bornholm disease from other acute chest pain etiologies. In September 2025, weekly outpatient and emergency visits for enterovirus infections in Taiwan reached 8,313, as reported by the Taiwan Centers for Disease Control, indicating a sustained need for supportive care even outside traditional peak seasons. The complexity introduced by diverse circulating viral strains, such as Enterovirus D68 accounting for 61.6% of reported enterovirus specimens in June 2025 according to the U.S. Centers for Disease Control and Prevention, further emphasizes the need for refined treatment approaches. Parallel to this, growing research and development investments in broad-spectrum antiviral therapeutics and vaccines are transforming the market by promoting the creation of new agents capable of targeting the Picornaviridae family, including Group B Coxsackieviruses. Public and private funding is increasingly channeled into translating basic virology research into clinical applications, aiming to introduce targeted therapies that offer more than the current non-specific pain relief. An example of this is the approximate $11.8 million awarded by the Advanced Research Projects Agency for Health (ARPA-H) to Mount Sinai Medical Center in October 2025 for developing broad-spectrum antiviral therapies, as reported by BioWorld. Such significant financial backing is crucial for advancing pipeline candidates through clinical trials, potentially introducing the first disease-modifying treatments for pleurodynia and substantially boosting the commercial potential of the sector.

Market Challenge

A significant impediment to the growth of the Global Pleurodynia Treatment Market is the frequent misdiagnosis of Bornholm disease, primarily due to its clinical presentation mimicking life-threatening cardiac events. The spasmodic chest pain characteristic of pleurodynia often closely resembles symptoms of myocardial infarction or pulmonary embolism, leading healthcare providers to prioritize extensive cardiac exclusionary tests over immediate viral symptom management. This diagnostic ambiguity delays the appropriate administration of analgesic or anti-inflammatory therapies, thereby narrowing the commercial opportunity for pleurodynia-specific interventions and diminishing the overall market volume for targeted treatments. This diagnostic challenge is particularly problematic given the substantial underlying prevalence of the causative viral agents, which often goes unrecognized in the context of specific pleurodynia treatment demand. For instance, the UK Health Security Agency reported an enterovirus and rhinovirus positivity rate of approximately 20.3% in monitored respiratory samples in November 2025. Despite such high viral circulation, the market struggles to capitalize on this patient base because a large proportion of these cases are clinically classified as non-specific chest pain or cardiac rule-outs rather than confirmed enteroviral myalgia, consequently suppressing the addressable revenue potential for the market.

Market Trends

The clinical management of pleurodynia is undergoing a rapid transformation toward non-opioid analgesic therapies, driven by the critical need to alleviate severe spasmodic chest pain without the associated risks of opioid dependence. This market shift is characterized by the emergence and commercialization of novel sodium channel inhibitors that specifically target peripheral pain signals linked to viral myalgia, offering a more sophisticated alternative to the generic non-steroidal anti-inflammatory drugs currently used as standard care. A notable development in this area was the U.S. Food and Drug Administration's approval of suzetrigine, a first-in-class oral NaV1.8 pain signal inhibitor, in January 2025, as reported by Vertex Pharmaceuticals. This drug directly addresses the acute pain management needs of approximately 80 million patients annually in the U.S., providing healthcare providers with a potent, targeted therapeutic option that aligns with the increasing emphasis on opioid-sparing protocols for acute viral conditions. Concurrently, the application of mRNA technology for enteroviral infections is revolutionizing the development of both prophylactic and therapeutic interventions for the Picornaviridae family, which includes Group B Coxsackieviruses. This trend leverages the inherent adaptability of mRNA platforms to create vaccines that can be quickly reformulated to match circulating strains, significantly reducing the lengthy development timelines associated with traditional inactivated vaccine candidates. Research published in Frontiers in Immunology in February 2025, for example, demonstrated that a nucleoside-modified mRNA vaccine candidate targeting the VP1 protein of Enterovirus A71 provided 100% protection against lethal viral challenge in preclinical models. Such promising results underscore the potential of mRNA technology to deliver precise protection against the specific viral agents responsible for Bornholm disease, marking a shift towards disease-modifying treatments beyond mere symptomatic relief.

Key Market Players

  • Bristol-Myers Squibb Co
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc
  • Sanofi SA
  • Johnson & Johnson
  • Merck & Co Inc.
  • GlaxoSmithKline PLC
  • Reckitt Benckiser PLC
  • Bayer AG
  • Novartis AG

Report Scope

In this report, the Global Pleurodynia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pleurodynia Treatment Market, By Diagnosis

  • Blood test
  • Culture test
  • X-ray

Pleurodynia Treatment Market, By Treatment

  • Analgesics or Painkillers
  • Immunoglobulin

Pleurodynia Treatment Market, By Mode of Administration

  • Oral
  • Injections or infusion

Pleurodynia Treatment Market, By End-User

  • Hospitals
  • Pharmacy
  • Others

Pleurodynia Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pleurodynia Treatment Market.

Available Customizations:

Global Pleurodynia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pleurodynia Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Diagnosis (Blood test, Culture test, X-ray)
    • 5.2.2. By Treatment (Analgesics or Painkillers, Immunoglobulin)
    • 5.2.3. By Mode of Administration (Oral, Injections or infusion)
    • 5.2.4. By End-User (Hospitals, Pharmacy, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Pleurodynia Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Diagnosis
    • 6.2.2. By Treatment
    • 6.2.3. By Mode of Administration
    • 6.2.4. By End-User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pleurodynia Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Diagnosis
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By Mode of Administration
        • 6.3.1.2.4. By End-User
    • 6.3.2. Canada Pleurodynia Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Diagnosis
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By Mode of Administration
        • 6.3.2.2.4. By End-User
    • 6.3.3. Mexico Pleurodynia Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Diagnosis
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By Mode of Administration
        • 6.3.3.2.4. By End-User

7. Europe Pleurodynia Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Diagnosis
    • 7.2.2. By Treatment
    • 7.2.3. By Mode of Administration
    • 7.2.4. By End-User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pleurodynia Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Diagnosis
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Mode of Administration
        • 7.3.1.2.4. By End-User
    • 7.3.2. France Pleurodynia Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Diagnosis
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Mode of Administration
        • 7.3.2.2.4. By End-User
    • 7.3.3. United Kingdom Pleurodynia Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Diagnosis
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Mode of Administration
        • 7.3.3.2.4. By End-User
    • 7.3.4. Italy Pleurodynia Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Diagnosis
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By Mode of Administration
        • 7.3.4.2.4. By End-User
    • 7.3.5. Spain Pleurodynia Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Diagnosis
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By Mode of Administration
        • 7.3.5.2.4. By End-User

8. Asia Pacific Pleurodynia Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Diagnosis
    • 8.2.2. By Treatment
    • 8.2.3. By Mode of Administration
    • 8.2.4. By End-User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pleurodynia Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Diagnosis
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Mode of Administration
        • 8.3.1.2.4. By End-User
    • 8.3.2. India Pleurodynia Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Diagnosis
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Mode of Administration
        • 8.3.2.2.4. By End-User
    • 8.3.3. Japan Pleurodynia Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Diagnosis
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Mode of Administration
        • 8.3.3.2.4. By End-User
    • 8.3.4. South Korea Pleurodynia Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Diagnosis
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Mode of Administration
        • 8.3.4.2.4. By End-User
    • 8.3.5. Australia Pleurodynia Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Diagnosis
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Mode of Administration
        • 8.3.5.2.4. By End-User

9. Middle East & Africa Pleurodynia Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Diagnosis
    • 9.2.2. By Treatment
    • 9.2.3. By Mode of Administration
    • 9.2.4. By End-User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pleurodynia Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Diagnosis
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Mode of Administration
        • 9.3.1.2.4. By End-User
    • 9.3.2. UAE Pleurodynia Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Diagnosis
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Mode of Administration
        • 9.3.2.2.4. By End-User
    • 9.3.3. South Africa Pleurodynia Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Diagnosis
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Mode of Administration
        • 9.3.3.2.4. By End-User

10. South America Pleurodynia Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Diagnosis
    • 10.2.2. By Treatment
    • 10.2.3. By Mode of Administration
    • 10.2.4. By End-User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pleurodynia Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Diagnosis
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Mode of Administration
        • 10.3.1.2.4. By End-User
    • 10.3.2. Colombia Pleurodynia Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Diagnosis
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Mode of Administration
        • 10.3.2.2.4. By End-User
    • 10.3.3. Argentina Pleurodynia Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Diagnosis
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Mode of Administration
        • 10.3.3.2.4. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pleurodynia Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Bristol-Myers Squibb Co
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd
  • 15.3. Pfizer Inc
  • 15.4. Sanofi SA
  • 15.5. Johnson & Johnson
  • 15.6. Merck & Co Inc.
  • 15.7. GlaxoSmithKline PLC
  • 15.8. Reckitt Benckiser PLC
  • 15.9. Bayer AG
  • 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer